AI-Based Drug Efficacy Evaluation Using Deep Learning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining the half-maximal inhibitory concentration (IC50) of drugs are time-consuming, require additional reagents that can be cytotoxic, and often destroy cells, making repeated measurements impossible.
Innovation Solution
The use of artificial intelligence-based systems, specifically deep learning models like convolutional neural networks (CNNs) and vision transformers, for analyzing histological images to classify drug efficacy without the need for cytotoxic reagents or cell lysis, allowing for non-destructive, high-throughput screening.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional IC50 determination methods using cytotoxic reagents (MTT, CCK-8, ATP assays) are employed, then measurement precision can be achieved, but the cells are destroyed preventing repeated measurements and requiring additional reagents that increase operational complexity
Solution Approach 1:
The patent replaces traditional mechanical/chemical assay methods (MTT reduction, CCK-8 colorimetry, ATP luminescence) with an optical imaging system that captures phase-contrast or brightfield images of cells. Deep learning algorithms then analyze these images to determine cell viability and calculate IC50 values, eliminating the need for cytotoxic reagents and cell lysis while preserving cell integrity for repeated measurements.
Solution Approach 2:
The patent introduces deep learning-based image analysis as an intermediary between cell treatment and IC50 determination. Instead of directly measuring metabolic activity through chemical reagents, the system uses trained neural networks to interpret morphological changes in cell images, serving as a non-invasive mediator that provides quantitative viability data without harming the cells.
2Measurement precision
If traditional IC50 determination methods are used, then drug potency can be measured, but significant time and effort are required for reagent application, incubation, and measurement procedures
Solution Approach 1:
The patent employs deep learning models that have been pre-trained on large datasets of cell images with known viability outcomes. This preliminary training allows the system to rapidly classify new cell images and determine IC50 values without requiring time-consuming reagent incubation or complex measurement procedures, significantly reducing the time needed for drug potency assessment.
Solution Approach 2:
The patent replaces time-intensive wet lab procedures (reagent addition, incubation, washing, lysing) with automated optical imaging and computational analysis. The deep learning system processes images rapidly, eliminating the need for prolonged incubation periods and manual intervention, thereby drastically reducing the overall time required for IC50 determination.
3Measurement precision
If additional reagents are applied for IC50 determination, then measurement accuracy can be improved, but operational complexity increases and costs increase due to reagent requirements
Solution Approach 1:
The patent extracts the essential measurement function from the complex chemical assay procedures and concentrates it into an optical imaging and image analysis system. By removing the need for multiple reagents (MTT, CCK-8, ATP reagents, lysis buffers) and their associated handling steps, the system simplifies operational complexity while maintaining measurement accuracy through deep learning-based image interpretation.
Solution Approach 2:
The patent implements a self-service measurement system where the deep learning model automatically analyzes cell images and calculates IC50 values without requiring manual reagent application or complex operational steps. The system performs calibration and validation using training datasets, then autonomously processes experimental data, reducing operational complexity and minimizing human intervention.
Data Source
AI summary
In some aspects, the disclosure is directed to methods and systems for artificial intelligence-based evaluation of pharmaceutical drug efficacy. Disclosed are implementations of deep learning that may be used to analyze histological images, study the differentiation of induced pluripotent stem cells, and perform binary classifications (live or dead, drug treated or untreated) on cancer cells or other target cells. Various type of classifiers or deep learning machines may be used in implementations, along with pre-processing in many implementations to further enhance distinctions between affected and unaffected cells.